Recursion Pharmaceuticals, Inc. (RXRX) Misses Q3 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q3 EPS of ($0.43), $0.04 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $10.53 million versus the consensus estimate of $11.24 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• RBC bullish on Kraft Heinz, sees return to growth in 2027
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M